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ABSTRACT
From 1985 to 2004, 49 patients with advanced myelodysplastic syndromes (MDS) ($5% blasts) or acute myeloid
leukemia (AML) transformed fromMDS underwent T cell depleted bone marrow or peripheral blood hemato-
poietic stem cell transplantation (HSCT) fromHLA-identical siblings following conditioning with a myeloabla-
tive regimen that included total body irradiation (44 patients) or busulfan (5 patients). Thirty-six patients
received chemotherapy (3 low dose and 33 induction doses) before conditioning, and 13 patients did not receive
any chemotherapy. Prior to transplantation, 22 of the 36 treated patients were in hematologic remission; 4 were
in a second refractory cytopenia phase (26 responders); 8 had failed to achieve remission; and 2 of the responders
had progression or relapse of their MDS (10 failures). No post-transplantation pharmacologic prophylaxis for
graft-versus-host disease (GVHD) was given. The median age was 48 yrs (range 13-61). Forty-five of the 49
patients engrafted; 2 had primary graft failure; and 2 died before engraftment. Only 3 patients developed acute
GVHD (aGVHD) (grades I and III) and 1 chronic GVHD (cGVHD). At 3 yrs post-transplantation, the overall
survival (OS) was 54% in the responders; 31% in the untreated group; and 0% in the failure group (P5.0004).
The disease free survival (DFS) was 50%, 15% and 0% in each group respectively (P5.0008). In multivariate
analysis, disease status before cytoreduction remained highly correlated with DFS (P\.001). The cumulative in-
cidence (CI) of relapse at 2-yrs post-transplantation for the responders was 23%; for the untreated group was
38%; and for the failures was 50%. The CI of non-relapse mortality at 2-yrs post-transplantation, for the
responders was 23%; for the untreated group was 38%; and for the failures was 40%. All survivors achieved a
Karnofsky Performance Status (KPS) of $90. These results indicate that patients with advanced MDS who
achieve and remain in remission or a second refractory cytopenia phase with chemotherapy before conditioning
can achieve successful long-term remissions following a myeloablative T cell depleted allogeneic HSCT.
 2008 American Society for Blood and Marrow Transplantation
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is currently the only curative treatment avail-
able for patients with myelodysplastic syndromes(MDS) [1-4].However, the high rate of post-transplan-
tation relapse compromises the success rate in advanced
forms of MDS ($5% blasts in the bone marrow or
.1% blasts in the peripheral blood) and acute myeloid
T cell depletion in advanced MDS 459leukemia (AML) transformed fromMDS [1-7]. This is
in contrast to the lower relapse rate and better disease
free survival (DFS) in patients with refractory anemia
or refractory cytopenia with multilineage dysplasia
with or without ringed sideroblasts [1-8]. Various ap-
proaches have been tried to reduce the incidence of
post-transplantation relapse in advanced MDS. The
use of more intensive preparative regimens combining
total body irradiation and busulfan has reduced the in-
cidence of relapse, but has resulted in increased regi-
men-related morbidity and mortality [9, 10].
The use of remission induction chemotherapy to
achieve remission before the administration of cytore-
ductive therapies for allogeneic hematopoietic stem
cell transplantation (HSCT) remains controversial.
Data from the European [11-13] and French registries
[14] showed improved DFS following allogeneic bone
marrow transplantation (BMT) from HLA-matched
siblings in MDS patients who were transplanted in he-
matologic remission compared with patients trans-
planted with refractory disease (DFS at 3 yrs of 25%
versus 15%). However, induction chemotherapy was
associated with a morbidity and mortality of 5 to
15% [14]. More recently, the FredHutchinson Cancer
Center reported their experience in 125 patients with
advanced MDS and AML evolved from MDS who
received transplants from HLA-identical siblings or
unrelated donors after myeloablative conditioning
regimens [15]. The relapse-free survival [RFS] at 3
yrs was similar in patients, regardless of whether or
not they underwent induction chemotherapy pre-
transplantation. However, relapse-free survival (RFS)
by response to induction chemotherapy was not given,
so any beneficial effect of pre-cytoreduction induction
chemotherapy could not be judged.
Although the early results ofT cell depletedmarrow
transplantation in patients with AML and chronic mye-
logenous leukemia clearly demonstrated that acute
and chronic graft-versus-host disease (aGVHD and
cGVHD) could be abrogated, the beneficial effect on
survival was compromised by the higher incidence of
graft rejection [16, 17] and post-transplantation relapse
[18]. Stepwise modifications of the myeloablative pre-
parative regimen have provided more intensive immu-
nosuppression and have reduced the incidence of graft
rejection and post-transplantation relapse in patients
with de novo AML who underwent transplantation in
remission to levels comparable to those seen in unmod-
ifiedmyeloablativeBMT[16, 19, 20].The4-yrDFSand
relapse rate in patients with AML in first remission have
been 77% and 3.2% respectively, and in patients with
AML in second remission, 50%and 12.5% respectively.
We now report the results of T cell-depleted trans-
plantation in 49 patients with advanced MDS, empha-
sizing their transplantation outcomes with regard to
pre-transplantation treatment and response to chemo-
therapy.MATERIALS AND METHODS
Patients
From January 1985 to December 2004, 49 pa-
tients with advanced MDS ($5% blasts in the bone
marrow or .1% blasts in the peripheral blood) or
AML evolved from MDS ($20% blasts in the pe-
ripheral blood or bone marrow) underwent T cell-
depleted bone marrow or peripheral blood HSCT
from HLA-identical siblings after preparation with
a myeloablative regimen at Memorial Sloan Ketter-
ing Cancer Center. Analysis of our early experience
with T cell depletion in MDS in 1998 showed
a higher incidence of graft failure and relapse in un-
treated patients with refractory anemia with excess
blasts (RAEB) 1 and RAEB 2, and in patients with
AML evolved from MDS who had failed induction
chemotherapy. Thereafter, patients with RAEB 1
and RAEB 2 were given chemotherapy before under-
going TCD HSCT, and if remission or a second re-
fractory anemia phase was not achieved, a non-T
cell-depleted (non-TCD) HSCT was offered. Also,
patients with AML who failed chemotherapy were
offered a non-TCD HSCT.
The patient and disease characteristics are summa-
rized inTable 1. All patients had been diagnosed as hav-
ingMDS at presentation and were at an advanced phase
or had transformed to AML when they were referred
for allogenic transplantation. The median age was 47.8
yrs, with 4 patients \20; 24 patients 20-50 yrs old;
and 21 patients .50. Forty-one patients had de novo
MDS, and only 8 patients had therapy-related MDS.
The MDS subtype and prognostic classification
at diagnosis and before transplantation were deter-
mined according to the WHO (World Health Orga-
nization) and IPSS (International Prognostic Scoring
System) criteria [21, 22]. Two patients had no chro-
mosome studies at diagnosis and the IPSS prognostic
category could not be determined. The patients who
responded to chemotherapy were divided into 2
groups: complete remission and second refractory
cytopenia phase. Complete hematologic remission
was defined as a cellular marrow with \5% blasts;
no overt dysplasia, neutrophils of .1,000/uL; plate-
lets of $ 100,000/uL; red cell transfusion indepen-
dent; and no circulating blasts [23, 24]. Second
refractory cytopenia phase was defined as a marrow
with \5% blasts, with or without dysplasia, and
with persistent pancytopenia with no circulating
blasts. Patients who failed to respond to chemother-
apy were classified for this analysis in their original
WHO subtype or IPSS score before administration
of chemotherapy.
All patients were fully informed of the risks of the
treatment and their written consent was obtained ac-
cording to the guidelines approved by our Institutional
Review Board.
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Thirty-six of the 49 patients received chemother-
apy before conditioning. Three patients were treated
with low dose chemotherapy and 33with full induction
chemotherapy. The most common induction chemo-
therapy regimen was a combination of standard dose
cytarabine given for 7 days and an anthracycline given
for 3 days.
Preparative Regimen
Forty-four patients were treated with a total body
irradiation (TBI)-based regimen and 5 patients with
a busulfan-based preparative regimen (Table 2). TBI
with lung shielding and testicular boost was given in
a hyperfractionated manner (1375-1550 cGy) (18, 19,
25). Cyclophosphamide (CY) was given at the dose
of 60 mg/kg/day for 2 days after TBI. Carboplatin
was administered before TBI as a continuous i.v. infu-
sion over 5 days, at the doses of 200, 250 or 300 mg/
m2/day. Diaziquone was also given before TBI as
a continuous infusion over 7 days, at doses of 8 or 12
Table 1. Patient and Disease Characteristics
Number of patients 49
Median age in yrs (range) 47.8 (13.3-60.6)
Recipient age distribution
#20 yrs 4
21-50 24
$51 21
Median time from diagnosis to transplant,
mos (range)
6.2 (1.8-53.2)
Etiology
Idiopathic 41
Post radiation and/or chemotherapy 8
Cytogenetics at diagnosis
Good 24
Intermediate 10
Poor 13
Failure 2
WHO MDS subtype at diagnosis
5 q- syndrome 1
Refractory cytopenia with multi-lineage
dysplasia
7
Refractory anemia with ringed sideroblasts 1
Refractory anemia with excess blasts 1 12
Refractory anemia with excess blasts 2 25
Chronic myelomonocytic leukemia 1 2
Chronic myelomonocytic leukemia 2 1
IPSS at presentation
Low risk 2
Intermediate risk I 14
Intermediate risk II 19
High risk 12
Unknown (no chromosome studies) 2
WHO MDS status before conditioning
Refractory anemia with excess blasts 1 6
Refractory anemia with excess blasts 2 8
AML 9
Complete remission 22
Refractory cytopenia in second phase 4 mg/kg/day. Thiotepa was given after TBI and before
CY at a dose of 5 mg/kg/day for 2 days. Fludarabine
was given after TBI at a dose of 25 mg/m2/day for 5
days. These regimens were part of phase 2 studies
conducted during the time period the patients in these
series underwent transplantation.
The use of preparative regimens containing solely
chemotherapy started only in 2001. Busulfan 0.8 mg/
kg was given by i.v. every 6 hours for 10 doses on
days -9 to -7; melphalan 70 mg/m2/day on days -7
and -6; and fludarabine 25 mg/m2/day on days -6
through day -2. Blood samples for pharmacokinetics
were collected at 0, 1, 2, 4 and 6 hrs after the first
dose of busulfan. Dose adjustments were made from
the 7th to the 10th doses to reach a steady-state level
of 600-900 ng/mL, with the desired level closer to
900 ng/mL.
Source of Hematopoietic Stem Cells
Thirty-two patients received a marrow graft; 12
a peripheral blood stem cell graft; and 5 a marrow graft
followed by a peripheral blood stem cell (PBSC) graft
because of low marrow cell dose. All donors were ge-
notypically matched siblings. Donor peripheral blood
stem cells were collected after mobilization with
Table 2. Patient and Donor Characteristics
Preparative regimen
TBI/CY 2
TBI/CYand carboplatin 8
TBI/CYand diaziquone 4
TBI/thiotepa/fludarabine 7
TBI/thiotepa/CY 23
Busulfan/melphalan/fludarabine 4
Busulfan/fludarabine 1
Rejection prophylaxis with
Anti-thymocyte globulin 35
None 14
Source of stem cell
Bone marrow 32
Peripheral blood 12
Bone marrow and peripheral blood 5
Median CD34 cell dose 106/kg (range) 1.17 (0.12-20.5)
CD34 (x108/kg) 0.8 (0.02-3.5)
Donor
Median age in yrs (range) 45 (11-65)
Number of males 27
Gender (donor:recipient)
M:F 9
M:M 17
F:M 10
F:F 13
Donor/Recipient CMV serology
Positive-positive 8
Positive-negative 8
Negative-positive 6
Negative-negative 10
Unavailable 17
TBI indicates total body irradiation; BU, busulfan; CY, cyclophos-
phamide.
T cell depletion in advanced MDS 461subcutaneous administration of rhG-CSF 8 mcg/kg
subcutaneously every 12 hrs for a total of 11 doses.
Two 3-4 hr apheresis were performed after the 9th
and 11th doses [20].
T Cell Depletion
The marrow grafts were depleted of T-cells by
soybean lectin agglutination and sheep red cell rosette
depletion [26]. The peripheral blood stem cells were
depleted of T cells first by positive CD34 selection us-
ing Cell Pro columns or Isolex 300i magnetic cell sep-
arator followed by sheep red cell rosette depletion [27].
Graft-versus-Host Disease Prophylaxis
Patients did not receive any pharmacologic post-
transplantation prophylaxis for GVHD.
Rejection Prophylaxis
Anti-thymocyte globulin (ATG) and methylpred-
nisolone were given to 35 patients to prevent graft re-
jection. ATG of equine origin (15-30 mg/kg/dose) was
given to 26 patients and of rabbit origin (2.5 mg/kg/
day) to 9 patients. Methylprednisolone was given on
the days ATG was administered at the dose of 2 mg/
kg/day. Of the 26 patients receiving equine ATG, 4 re-
ceived it pre-transplantation on days -4 and -5; and 22
received it post-transplantation every other day from
day15 to1 13. All 5 patients prepared with the busul-
fan-containing regimen and 4 patients prepared with
the TBI-based regimen received rabbit ATG pre-
transplantation on days -3 and -2. The administration
of ATG was switched from post-transplantation to
pre-transplantation to assess the impact of time of
administration on T cell function recovery.
Supportive Care
The patients included in this series underwent
transplantation over a period of 19 years during which
time supportive care measures used in allogeneic
HSCT improved [20]. In general, patients were hospi-
talized in single rooms on reverse isolation. They re-
ceived acyclovir prophylaxis against Herpes simplex
and zoster infections; fluconazole for fungal prophy-
laxis (or low dose AmBisome or voriconazole if history
of aspergillosis); and atovaquone for toxoplasmosis
prophylaxis in patients at risk. Prophylactic anti-bacte-
rials were not given in the peri-transplantation period.
The patients conditioned with busulfan received sei-
zure prophylaxis with phenytoin. Recombinant human
granulocyte colony stimulating factor (G-CSF) was
given in the early post-transplantation period when
the cell dose was low or patients had fever or infection
despite appropriate antibacterials. No other cytokines
were administered. Patients with CMV viremia were
treated with ganciclovir or Foscarnet, and those diag-nosedmore recently with EBV viremia received Ritux-
imab therapy.
Older recipients of T cell-depleted transplants
have delayed recovery of immune function [28]. Im-
mune function recovery was monitored by flow cyto-
metric analysis of T cell subpopulations and response
to themitogen phytohemagglutinin (PHA) [28]. Infec-
tion prophylaxis for Pneumocystis jiroveci, and DNA
Herpes viruses was continued until patients achieved
a CD4 count of .200/mL and a PHA within 75% of
lower limit of normal.
Donor Leukocyte Infusions (DLI)
Nine patients received donor leukocyte infusions
(DLI): 4 for relapseand1 for increasingmixedchimerism
with no evidence of hematologic relapse. The remaining
4 patients receivedDLI as treatment for anopportunistic
infection: one Epstein-Barr virus associated lymphopro-
liferative disorder; one JC virus associated multifocal
leukoencephalopathy; one acyclovir-resistant Herpes
simplex virus infection; and one persistent Mycobacte-
rium haemophilum cutaneous infection.
Outcome Definition
Neutrophil engraftment was defined as the first of
3 consecutive days with an absolute neutrophil count
(ANC)$500/ml. Engraftment was confirmed by docu-
mentation of chimerism in bone marrow cells using
karyotype or fluorescent in situ hybridization (FISH)
of the X and Y chromosome in sex mismatched do-
nor-recipient pairs and by measurement of DNA
restriction fragment length polymorphisms or short
tandem repeats in sex-matched pairs.
Primary graft failure was defined as the absence of
neutrophil recovery ($500/ml) by day 28 and bone
marrow biopsy with #5% cellularity. Secondary graft
failure was defined as loss of ANC to\500/mm3 after
primary engraftment with bone marrow biopsy show-
ing #5% cellularity.
Acute and chronic GVHD were evaluated ac-
cording to established criteria [29-31] in patients
who survived $21 and $100 days with engraftment,
respectively.
Hematologic relapse was defined as the recurrence
of cytopenias associated with marrow morphologic
changes diagnostic of MDS. Cytogenetic relapse was
defined as the recurrence of pre-transplantation chro-
mosome abnormalities.
For patients who relapsed and died, relapse was the
primary cause of death even if the patient died of other
events. Causes of death other than relapse were consid-
ered to represent competing risks. GVHDwas the pri-
mary cause of death if the patient developed a fatal
complication such as an infection while receiving sys-
temic therapy for GVHD. Infection was the primary
cause of death if it occurred in the absence of graft
462 H. Castro-Malaspina et al.failure, GVHD, and relapse. Non-relapse mortality
(NRM) was defined as death without evidence of he-
matologic relapse. In this case, relapse was considered
a competing risk, and patients who were alive without
relapse were censored at last follow-up.
Statistical Analysis
The primary endpoints of this study were DFS,
RFS, and NRM. The Kaplan-Meier estimate was
used to compute DFS probability over time [32],
whereas the cumulative incidence function was used
to estimate the probabilities for the time to relapse
and non-relapse mortality [33]. The prognostic factors
considered in this analysis were: age at diagnosis (#50
vs .50); etiology (primary versus treatment related);
WHO at diagnosis; blasts at diagnosis; cytogenetic
risk at diagnosis; IPSS at diagnosis; WHO at progres-
sion before chemotherapy; number of courses of induc-
tion; administration of consolidation chemotherapy;
disease status before conditioning; preparative regi-
men; and CD34 cell dose. The log-rank statistics eval-
uated the marginal effect of the prognostic factors on
DFS [34, 35]. Gray’s statistics evaluated the individual
effects of these factors on the time to relapse and non-
relapse mortality [36]. A proportional hazards model
was used to determine the joint prognostic factors
that predicted DFS.
RESULTS
Disease Status Before Conditioning
Thirteen patients did not receive any chemother-
apy before conditioning and 36 patients received
chemotherapy, 33 a full course of induction chemo-
therapy, and 3 low dose chemotherapy (Table 3). Of
the 33 patients receiving induction chemotherapy, 22
were in hematologic remission (19 after one course
and 3 after 2 courses); 3 in a second refractory cytope-
nia phase; and 8 failed to respond (5 patients received 2
courses of induction chemotherapy). Of the 3 patients
receiving low dose chemotherapy, 2 receiving azaciti-
dine achieved a second refractory cytopenia phase;
and one patient receiving cytarabine achieved hemato-
logic and cytogenetic remission.
Only 3 (13.6%) of the 22 complete responders to
induction chemotherapy had high-risk cytogenetics,
Table 3. Chemotherapy Before Conditioning in 36 Patients
Low dose chemotherapy (azacitidine and cytarabine) 3 (8%)
High dose chemotherapy 33 (92%)
Anthracycline and standard dose Cytarabine 19 (53%)
Anthracycline and high dose Cytarabine 7 (19%)
Anthracycline and etoposide 1 (3%)
Etoposide and high dose Cytarabine 4 (11%)
Etoposide, anthracycline and Cytarabine 1 (3%)
FLAG (fludarabine, Cytarabine and G-CSF) 1 (3%)whereas 4 (50%) of the 8 failures had high-risk cytoge-
netics. Ten of these 22 patients received a course of
consolidation chemotherapy before conditioning for
transplantation.
Of the 23 patients achieving complete remission
with induction or low dose chemotherapy, only one re-
lapsed before transplantation. One of the 4 patients
achieving a second refractory cytopenia phase had dis-
ease progression before transplantation. Thus, there
were 26 patients who remained in remission or in a sec-
ond refractory cytopenia phase before conditioning.
The 2 patients whose disease relapsed or progressed
before pre-transplantation cytoreduction were ana-
lyzed together with the 8 patients who failed to achieve
remission (10 failures to chemotherapy).
Engraftment
Of the 49 patients, 2 died before engraftment, 2
had primary graft failure, and 45 engrafted. Two pa-
tients subsequently developed secondary graft failure
(Table 4). The median time to neutrophil engraftment
was 13 days (range 8-32). All 4 patients who developed
primary or secondary graft failure had active disease
pre-transplantation, and 3 had not received any che-
motherapy before conditioning. All but one of the graft
failure patients received ATG in the peri-transplanta-
tionperiod.Chimerismstudies revealedapredominance
Table 4. Transplant Outcomes in 49 High Risk MDS Patients Receiving
a T Cell Depleted HSCT From an HLA-Matched Sibling
Untreated
n513
Failures
n510
Responders
n526
Engraftment* 12 8* 25*
Time to engraftment
(days range)
9-22 8-32 9-21
Graft Failure 3 1 0
Regimen-related toxicity 0 0 1
EBV-related LPD 2 0 0
Acute GvHD 1 1 1
Chronic GvHD 0 0 1
Relapse 5 5 6
Causes of death
Graft failure 3 1 0
Regimen-related (VOD) 0 0 1
Graft-versus-host disease 0 1 1
Infections
Bacterial 0 2 4
HZV encephalitis 0 0 1
PML 0 0 1
EBV 2 0 0
Other 1 1** 0
Relapse 4 5 5
Alive in remission 2 0 13
Median follow-up (mo) 9.3 5.8 36
Range 0.8-68.6 0.2-27.9 0.6-213.9
*2 patients non-evaluable for engraftment and 2 had primary graft
failure.
**this patient died of metastatic renal cell carcinoma in remission of
her MDS.
T cell depletion in advanced MDS 463of host cells in each of the 3 cases that were adequately
evaluated. Persistent or relapsed disease was thought to
be the cause of graft failure in all 4 cases. One patient
died before a second graft could be obtained. The
other 3 patients received a second bone marrow (2
patients) or a peripheral blood stem cell(PBSC) trans-
plantation (1 patient) after secondary conditioning
with cyclophosphamide and ATG. However, all died
of complications associated with pancytopenia within
44-68 days of documented graft failure.
Graft-versus-Host Disease
Of the 45 patients who engrafted and survived at
least 28 days, 2 developed aGVHD (grades I and III,
respectively) (Table 4). Another patient who received
DLI (105 CD3 cells/kg) for acyclovir resistant Herpes
simplex virus at 11 mos post-transplantation also de-
veloped acute GVHD (grade I). This is the only pa-
tient of 43 surviving at least 100 days who developed
extensive cGVHD.
Relapse
Sixteen of the 49 patients had documented relapse
of their MDS after transplantation. Five of these re-
lapses occurred in 13 patients who did not receive
any chemotherapy before conditioning. Relapses
were also seen in 5 of the 10 patients who failed to re-
spond to induction chemotherapy (8 patients) or had
relapsed with MDS before conditioning (2 patients)
(Table 4). Six of the 26 patients who either remained
in complete remission (22 patients) or who had at-
tained a second refractory cytopenia phase before con-
ditioning (4 patients) also relapsed (Table 4). The
cumulative incidence of relapse at 2 yrs for all patients
was 31.6% (Figure 1). The cumulative incidence of re-
lapse with respect to response to pre-conditioning che-
motherapy was 38% among those not treated, 50% of
the failures, and 23% among the responders to chemo-
therapy (P5.248)(Figure 1). All relapses occurred
within 2 yrs of transplantation with a median time to
relapse of 9.6 mos.
Relapse was treated with DLI in 4 patients; a sec-
ond transplant in 3 patients; and supportive therapy
in 9 patients. Two patients with a high blast count
(.20%), and one patient with 10% blasts did not re-
spond to DLI. One patient who had a cytogenetic re-
lapse with no excess of blasts achieved full donor
chimerism after DLI and remains in remission. Three
patients underwent a second transplantation, 2 from
the same donor and one from a second donor. Two
of these transplants were T cell replete and one T
cell-depleted. One patient undergoing a second trans-
plantation died of complications associated with
GVHD, and the 2 other patients died of relapsed
MDS. Of the 16 patients with relapsed disease 2 are
alive, one in remission and another one with disease.In the 22 patients who were in complete remission
prior to conditioning, cytogenetic risk category was
correlated with relapse (P\.001). In contrast, WHO
classification at diagnosis or at progression before che-
motherapy, IPSS at diagnosis, number of induction
courses, administration of consolidation, preparative
regimen (TBI, thiotepa and cyclophosphamide versus
TBI, thiotepa, and fludarabine), and CD34 cell dose
did not correlate with relapse.
Survival, Disease-Free Survival, and Functional
Status
Of the 49 patients, 16 are alive, 15 in remission,
and 1 with relapsed MDS. The median follow-up for
all patients is 22 mos (range 0.26-213) and for the sur-
viving patients is 77 mos. The OS and DFS for all pa-
tients are shown in Figure 2. The OS and DFS at 3 yrs
were 36.7% and 30.6%, respectively. All 15 surviving
patients surviving more than 2 yrs have achieved a Kar-
nofsky Performance Status (KPS) of $90.
Of the 13 patients not treated before conditioning,
3 are alive, one with relapsed MDS, 2 with no evidence
of MDS, but one has recurrence of her Ewing Sar-
coma. All of the 10 failures to chemotherapy have
died. Of the 22 complete responders, 10 are alive
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Figure 1. Cumulative incidence of relapse. A, all patients. B, by
response to chemotherapy before conditioning.
464 H. Castro-Malaspina et al.with no evidence of disease. Among the 4 patients who
achieved a second refractory cytopenia phase, 3 are
alive in remission, including one after DLI. The OS
at 3 years was 54% for the responders, 31% for the un-
treated, and 0% for the failures (P5.0004). TheDFS at
3 yrs was 45%, 15% and 0% respectively (P5.0008)
(Figure 2). In multivariate analysis, disease status prior
to conditioning remained highly correlated with DFS
(P\.001) and there were no other factors that indepen-
dently predicted DFS.
Comparison of the untreated patients versus the
patients treated with chemotherapy before condition-
ing irrespective of response showed a DFS at 3 yrs of
15.4% for the 13 patients who did not receive chemo-
therapy and 33% for the 36 patients who received low
or induction dose chemotherapy (P5.18).
Causes of Death and Non-Relapsed Related
Mortality
Nineteen patients died of non-relapse causes and
14 of disease relapse (Table 4). Infectious complica-
tions were the main cause of NRM. Bacteria were
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Figure 2. Probability of survival. A, Overall survival and disease-free
survival (DFS) for all patients. B, DFS by response to chemotherapy
before conditioning. the most common cause of infections occurring before
day 100 post-transplantation, whereas viral infections
predominated thereafter. All patients who died of in-
fections in the late post-transplantation period had
poor immune function as defined by a low CD4 count
and poor response to mitogens. Graft failure was only
seen in the untreated patients who had active disease
before transplantation. Graft-versus-host disease was
the cause of death in only one patient who received
DLI. Regimen-related deaths were rare, as only one
patient developed hepatic veno-occlusive disease.
The cumulative incidence of NRM at 2 yrs for the
whole group was 30%, with the lowest relapse rate in
the group of patients in remission before cytoreduc-
tion. The cumulative incidence of NRM for the re-
sponders was 23%; for the untreated group was 38%;
and for the failures to chemotherapy was 40%
(P5.252) (Figure 3). None of the parameters examined
was associated with an increased NRM.
DISCUSSION
The use of pre-transplantion chemotherapy and its
impact on transplantation outcome is controversial in
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Figure 3. Cumulative incidence of non-relapse mortality. A, all pa-
tients. B, by response to chemotherapy before conditioning.
T cell depletion in advanced MDS 465unmodified myeloablative HCST for advanced MDS.
Data from2multi-center European studies including pa-
tients with de novo and therapy-related MDS [13, 14]
showed a benefit of achieving complete remission be-
fore transplantation, when compared with patients
who had failed induction chemotherapy. In contrast,
data from the FredHutchinson Cancer Center in Seat-
tle [15] showed no benefit of induction chemotherapy
when comparing the survival between treated (re-
sponders and failures together) and untreated patients.
The RFS at 3 yrs in these groups was only 13% and
26% respectively. Relapse was nevertheless the main
cause of death in the untreated group, 64% versus
21% in the treated group. The value of induction che-
motherapy before unmodified myeloablative HSCT
thus remains unclear. An ongoing multi-center pro-
spective trial [38] will hopefully clarify the role of in-
duction chemotherapy in this setting.
This relatively large, single-center series, with
amedian follow-up of 6 yrs for survivors shows that pa-
tients with advanced MDS can achieve a significant
long-term DFS after a T cell-depleted myeloablative
allogeneic HSCT. This success depends on the
achievement of sustained remission or a second refrac-
tory cytopenia phase after receiving induction or low
dose chemotherapy before transplantation condition-
ing. The survival benefit is largely due to a decrease
in post-transplantation relapse as well as GVHD and
graft failure. Similar observations were made in a small
series of 15 patients with advanced MDS and AML
post-MDSwho receivedmyeloablativeT cell-depleted
bone marrow grafts fromHLA-matched siblings in re-
mission after induction chemotherapy [37]. There are
no other publications specifically reporting the results
of myeloablative T cell-depleted transplantation in ad-
vanced MDS.
The relapse rate afterT cell-depletedmyeloablative
transplantation in our MDS patients in remission or
second refractory cytopenia phase is similar to that
seen in recipients of unmodified myeloablative trans-
plantation [4, 13, 14, 15, 39-43].This suggests thatmye-
loablative conditioning regimens may help eliminate
residualMDS/leukemic clones. Also, donor-derived ef-
fector cells other than mature T cells contributing to
GVHD may redevelop from precursors present in a T
cell-depleted graft to provide enhanced resistance to
the patient’s disease. Candidates include donor NK
cells that emerge early after T cell-depleted grafts [44,
45]. Similar observations and conclusions apply to pa-
tients with de novo AML in first and second remission
treated with T cell-depleted transplants at our institu-
tion, who had relapse rates comparable to or better
than those seen after unmodified myeloablative trans-
plantation [19, 20]. On the other hand, the higher inci-
dence of relapse in our untreated and induction failure
patients suggests that the preparative regimen alone
can not compensate for optimal disease control pre-transplantation. A graft-versus-MDS effect is also oper-
ative in recipients of unmodified allografts, but there is
much greater overlap with GVHD. The graft-versus-
MDS effect has been well documented in large retro-
spective studies that showed a lower relapse rate in
patients with GVHD following myeloablative [46] or
non-myeloablative transplants [47-51]. It has been con-
firmedby theobservation that patients treatedwithDLI
for post-transplantation relapse can achieve remission
again [52-55]. Our data suggest that T cell-depleted
transplants should be limited to patients with advanced
MDS whose disease is in remission or who have a low
blast count, unless specific alloreactive donor cytotoxic
cells are available to be given in the post-transplantation
period. Leukemia associated antigens likeWT1, which
are highly expressed in MDS patients [56-59], are cur-
rently being used to generate leukemia specific T cells
of donor origin [60-61]. These T cells may decrease
the risk of relapsewithout increasing the risk ofGVHD.
The most common causes of NRM in this series
were infections and graft failure. The frequency of
these complications was lower in the responder group.
However, infectious complications occurring early
(1 case) and particularly late (.3 mos) post-transplan-
tation (5 cases) were the main cause of NRM in the re-
sponders and had a significant impact on survival. All
patients who died of infections in the late post-trans-
plantation period had quantitative and qualitative T
cell deficiencies. Slow or poor T cell reconstitution
following T cell-depleted transplantation is due in
part to the administration of ATG for rejection pro-
phylaxis and to the recipient’s age, as described by
Small et al [28]. All 5 patients who died of late infec-
tion were $50 yrs old. Elimination of ATG in our
most recent trial has resulted in substantial improve-
ment of immune recovery post-transplantation [62].
However, for patients $50 yrs, numerical and func-
tional T cell recovery is still delayed, likely reflecting
age-associated impairments to the recovery of thymo-
poiesis. Newer approaches such as administration of
interleukin 7 (IL-7) or keratinocyte growth factor
(KGF), which stimulate thymopoiesis and T cell re-
constitution in experimental animals [63-70], are cur-
rently being tested for their capacity to accelerate
immune recovery in older patients who have under-
gone allogeneic HSCT.
Graft failure was a notable non-relapse complica-
tion in the untreated group despite prophylaxis with
ATG.Most of these patients had a high disease burden
with high blast counts before transplantation. The
most likely mechanism was persistent disease, but
this could not be proved in the absence of autopsies.
Graft failure attributed to persistent disease has also
been noted after unmodified myeloablative HSCT
for advanced MDS [4].
In contrast to unmodified HSCT, the incidence
of acute and chronic GVHD in this series was
466 H. Castro-Malaspina et al.extremely low. Three patients developed aGVHD,
and only one patient developed chronic GVHD after
DLI. Moreover, GVHD was the cause of non-relapse
death in only 2 patients. This is very similar to our
experience in patients with de novo AML in first
and second remission [20]. Acute and chronic
GvHD remain the main cause of morbidity and mor-
tality after unmodified transplantation following
myeloablative [3, 4, 6, 7, 9-15] or reduced-intensity
conditioning [43, 47-51], particularly in older pa-
tients, who constitute the majority of patients with
MDS. There has been a great deal of interest in the
use of non-myeloablative or reduced intensity trans-
plantation in older patients with MDS, because of
the reduction in aGVHD and early NRM[49-51].
The incidence of cGVHD and late transplantation-
related mortality, however, has been comparable to
that seen in myeloablative transplantation. Moreover,
disease relapse in patients either in remission or with
increased blasts has also been higher than that ob-
served after myeloablative conditioning and either
T cell replete transplantation [43, 48, 49, 51] or as
shown in this series, T cell-depleted grafts. While
the addition of antithymocyte globulin [71, 72] or
alemtuzumab [73-75] to reduced-intensity prepara-
tive regimens has decreased the incidence of
GVHD, the rate of post-transplantation relapse in
patients with advanced MDS has remained high.
This suggests that the intensity of the preparative
regimen is important in preventing post-transplanta-
tion relapse in these patients. Our T cell-depleted
myeloablative transplantation approach offers to pa-
tients with advanced MDS in remission and without
prohibitive co-morbidities the possibility of durable
remission with minimal risk of GVHD. The use of
newer approaches to improve immune reconstitution
in these patients should further improve the overall
and disease-free survival.
In summary, we show that patients with advanced
MDS can achieve a significant long- term DFS after T
cell-depleted allogeneic HSCT. Such success depends
on successful chemotherapy achieving either sustained
remission or a second refractory cytopenia phase be-
fore undergoing cytoreduction for transplantation.
This approach markedly reduces 2 major obstacles
limiting the success of allogenic transplantation, dis-
ease relapse and GVHD. Infections were the most
common cause of non-relapse mortality especially in
older patients. Thus, improved prophylaxis, or new
agents that enhance recovery of immune function
may improve the survival of patients with advanced
MDS after T cell-depleted HSCT. Finally, demon-
stration of the superiority of this approach over
other types of transplantation will require prospec-
tive trials comparing this type of transplantation to
unmodified myeloablative or non-myeloablative
allogeneic HSCT.REFERENCES
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